Blood Operators to Plasma: An Anonymized Case Study in the Hidden Complexity

Why asset transfer isn't the same as operational translation

By Aurea Vita Advisors (AVA) | 6 min read

Both blood banks and commercial plasma collection companies share an overarching goal: To improve patients' health. 

To that truth, blood banks have everything a plasma operator would want: regulatory discipline, existing phlebotomy infrastructure, a board and management team that understands FDA/EMA (or the nation's governing Health Ministry) requirements, and staff accustomed to managing precise donor safety compliance and pristine sample/product integrity. Both industries share a fundamental mission—ensuring patients receive the life-saving therapies they depend on. So it should be straightforward to translate those assets into a plasma collection operation. But straightforward translation often stumbles without deliberate operational rethinking.

Last year, Aurea Vita Advisors (AVA) worked with a US blood bank operator preparing to launch a distinct plasma collection center in a new US market, several states away from where the parent organization had built its stellar reputation. The operator had the regulatory knowledge, the infrastructure mindset, and the experience base to succeed. What they didn't have was a translation layer—a systematic way to rebuild how they thought about donor acquisition, workforce management, and service delivery for an entirely different business model.

That translation took six months of deliberate operational rethinking. The result: a facility ramping to approximately 40 plasma donors per day in a high-density competitive market, FDA pre-licensure compliance, and with unit economics tracking to plan. More importantly, the engagement revealed why some blood banks exploring plasma succeed while others struggle, despite possessing all the foundational pieces.

At a Glance

Blood bank and plasma center operations overlap in regulatory framework and mission but diverge completely in business model—blood banks operate primarily on appointment density and supply scarcity; commercial plasma centers operate on quasi-retail throughput and walk-in variability.

Operational translation required rebuilding three core assumptions: donor motivation and acquisition strategy, workforce management and performance incentives, and service delivery architecture for high-volume retail traffic.

Pre-licensure, the center reached ~40 donors per day in a high-density competitive market with unit economics tracking to plan—demonstrating that the translation work preceded and enabled execution.

The Situation: Assets ≠ Outcomes

Blood banks and plasma centers operate under overlapping FDA frameworks. They share cold-chain discipline, sample tracking, and quality systems. But they are structurally different businesses with different operational demands; and both models are appropriate for their respective organizations.

A blood bank operates on appointment density and supply scarcity—donors are scheduled weeks in advance, availability is always constrained, and the operation's job is to maximize unit collection per session. Blood donors commit to scheduled appointments driven largely by altruistic calling and community responsibility to help patients with critical medical needs.

Large scale plasma collection operates on quasi-retail dynamics. Donors are typically walk-ins depending on the organization. Both blood and plasma donors are mission-aligned—they want to help patients receive critical medications and therapies; but plasma donors donate repeatedly only if the location is convenient, the process moves fast, and the experience is predictable—with compensation that acknowledges their significant time investment each week. A plasma center can't manage on scarcity; it manages on throughput. Cost per liter isn't determined by operational excellence alone—it's determined by how many donors can compliantly move through the facility per day and how many times the individuals return.

This operator understood blood banking operations with exceptional depth. Yet in this pivot, they didn't yet understand plasma as a quasi-retail operation requiring different execution models.

The Engagement: Rebuilding Operational Assumptions

Three operational assumptions had to be rebuilt from scratch with this client:

1) Donor Motivations and Market Mapping

Blood donors and plasma donors are both mission-driven, but they respond to different incentive structures and accessibility models. The demographic profiles don't overlap cleanly.

The operator had to stop recruiting from their existing blood donor base and instead map the market for plasma-eligible donors in a state and city where their organization had zero market presence. That meant understanding local demographic income bands, employment patterns, transit routes, community cultural tendencies, and competitor saturation—not just regulatory compliance. It required thinking like a retail operator while maintaining blood bank-level quality standards.

2) Workforce Management and Performance Architecture

Blood banks and plasma centers both demand rigorous quality control and sample integrity. The operational constraint in a blood bank is donor availability. The constraint in a plasma center is how efficiently the phlebotomy and processing teams can progress donors and units through the facility with excellent service delivery while maintaining those high quality standards.

Generally speaking, the operator had to rebuild staffing models, compensation structures, and performance metrics around throughput velocity rather than appointment fulfillment. Blood bank operators optimize for reliability and sample/product integrity. Plasma operators optimize for the same quality standards AND high-volume throughput, with additional emphasis on repeat-donor retention and predictable service delivery. The skill sets overlap significantly, but the incentive structures and performance metrics don't.

3) Service Delivery Architecture

A blood bank is appointment-based with fixed capacity and scheduled flow. A plasma center operates on extended weekly hours, walk-in access, and demand variability. Parking, facility layout, staffing distribution, wait-time management—all of it has to support retail and/or hospitality dynamics, not appointment logistics.

This particular operator had expected to apply blood bank phlebotomy discipline directly to plasma collection. Instead, they discovered that plasma throughput demands rethinking everything from facility footprint to autopheresis device management to BECS integration to donor communication to how staff manage peak-hour volume without compromising quality or safety.

The Result: Execution at Scale

Six months from engagement to operational launch in a new state, in a high-density competitive market. Donor volume ramped from zero to ~40 donors per day. The operator achieved this without FDA licensure (current product is quarantined pending FDA pre-licensure inspection), which means they're tracking unit economics and operational discipline with no revenue recognition yet.

An FDA pre-license inspection is scheduled within the next 90 days, with internal quality audits reporting top-notch compliance. Assuming standard outcomes, the operator will transition from quarantine to revenue-generating inventory by Q42026. More importantly, once operational, the center will expand access to plasma-derived therapeutics that patients with rare diseases, bleeding disorders, and immunodeficiencies depend on—extending the same mission-driven mandate that defined their blood bank operations into a new therapeutic category.

What the Translation Revealed

"We had spent years perfecting blood bank operations. When we started plasma, we assumed we could execute that same playbook. Six months in, we realized we weren't replicating anything operationally—we were replacing it. The regulatory framework stayed the same, but everything else—how we think about our donors, how we staff, how we measure success, our SOPs, our technology infrastructure—had to be rebuilt or implemented differently. Asset transfer was the illusion; the real work was operational translation."

— Blood Bank Operator (anonymized client)

"Most blood organizations walk into plasma thinking their infrastructure is the hard part. It's not. The hard part is accepting that you're running a different business—one that still serves patients but through a different operational model. This operator understood that distinction before they committed capital. That clarity is why they've been successful."

— Charles Auger, Co-Founder, Aurea Vita Advisors

"Blood bank operators bring exceptional regulatory discipline and quality rigor. What they often lack is clarity about unit economics in a quasi-retail environment. This operator did the translation work before they opened the doors. We helped them stress-test their assumptions about donor behavior, throughput, and cost per liter—the operational levers that don't exist in blood banking but define plasma economics. That translation is what separates operators who succeed from those who struggle."

— Chris Barber, Co-Founder, Aurea Vita Advisors

Why This Matters for Other Operators

Some blood banks have been skeptical of plasma collectors in their markets for decades, often framing plasma operators as competitors for the same donor pool. That framing was never accurate—the donors are different, the economics are different, and the operational requirements are different. More fundamentally, both industries serve the same mission: ensuring patients have access to life-saving therapies.

What's happening now is quieter: blood banks are discovering that plasma collection is a viable asset play that leverages existing infrastructure and regulatory maturity—while expanding access to the plasma-derived therapeutics that patients with rare diseases, bleeding disorders, and immunodeficiencies depend on.

The operators who succeed are the ones who treat plasma as a new business rather than an extension of the old one. They translate their operational discipline, not their operational procedures. They rebuild their thinking about who donors are, why donors show up, and what it takes to move them through the facility at scale. Operators who struggle are the ones who expect asset transfer alone to do the work—who assume that regulatory knowledge and infrastructure will carry the day without deliberate operational rethinking.

The advisory work happens in the gap between those two outcomes.

For blood banks with the strategic vision to enter plasma collection, the competitive advantage isn't regulatory knowledge or cold-chain discipline—you already have those as foundational strengths. It's clarity about unit economics, throughput architecture, and donor behavior in a quasi-retail model. That clarity is what separates successful plasma operators from those who struggle. It's also what allows blood banks to leverage their exceptional infrastructure and regulatory maturity into a new therapeutic mission.

What Comes Next

If your blood bank is considering a plasma program, the question isn't whether you can operate one. You probably can. The question is whether you've done the operational translation work before you commit capital to a lease, staff a facility, or start recruiting in a market you don't yet understand.

That's where the real leverage sits—not in asset transfer, but in stress-testing assumptions about donor behavior, market structure, and unit economics before you build or acquire. The operators who do this work first are the ones who scale successfully while maintaining the quality and mission-driven culture that blood banks have always stood for.

Work With AVA

AVA provides site selection, real estate due diligence, regulatory strategy, and plasma center operations management to blood banks and plasma operators in most nations at every stage: pre-launch evaluation, market entry, multi-center scaling, and M&A integration. Whether you're a blood bank exploring diversification or an established plasma operator looking to scale, we help you translate strategy into operational clarity and execution.

________________________________________________________________________________

About Aurea Vita Advisors

Aurea Vita Advisors (AVA) is the only consulting firm specializing in international human blood plasma collection led by former plasma collection executives. Founded by industry veterans Charles Auger and Chris Barber, the firm brings a combined 74 years of hands-on plasma industry experience to site selection, regulatory strategy, M&A due diligence, fleet infrastructure build-out, and operations management for plasma collection centers and fractionators worldwide. AVA's advisors have launched 82 centers organically and integrated 78 more through M&A, with engagements spanning five countries and three continents. For more information, visit aureavitaadvisors.com.

Plasma Collection, Blood Bank Diversification, Operational Translation, Plasma Center Launch, Donor Demographics, Retail Operations, Cost Per Liter, Case Study, Workforce Management, Service Delivery